SCHEMBL630265

SCHEMBL630265

CC1Cc2cc(N3CC(=O)NS3(=O)=O)c(OCc3ccccc3)cc2S1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.45
CREBBP Q92793 4/20 0.38
BRD4 O60885 4/20 0.38
PDE4B Q07343 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
SNRNP200 O75643 1/20 0.35
CHRNA7 P36544 2/20 0.34
HTR6 P50406 1/20 0.33
CRBN Q96SW2 1/20 0.33
IKZF3 Q9UKT9 1/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL630221 0.80 PTPN1 (0.49) PTPN1BRD4SNRNP200CHRNA7MAOA
SCHEMBL630163 0.79 PTPN1 (0.43) PTPN1CREBBPBRD4PDE4BSNRNP200
SCHEMBL4646378 0.77 PTPN1 (0.51) PTPN1BRD4SNRNP200CHRNA7HTR6
SCHEMBL12056127 0.77 PTPN1 (0.50) PTPN1CHRNA7HTR6MAOB
SCHEMBL630226 0.76 PTPN1 (0.48) PTPN1
SCHEMBL3005189 0.75 PTPN1 (0.48) PTPN1BRD4SNRNP200MAOAMAOB
SCHEMBL3920457 0.74 PTPN1 (0.61) PTPN1BRD4SNRNP200HTR1ASLC6A2
SCHEMBL3917446 0.74 PTPN1 (0.47) PTPN1SNRNP200CHRNA7CRBNIKZF3
SCHEMBL646919 0.74 PTPN1 (0.47) PTPN1SNRNP200CHRNA7HTR1ASLC6A2
SCHEMBL3917425 0.74 PTPN1 (0.47) PTPN1SNRNP200SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC PTPN1 23/4885CREBBP 739/4885BRD4 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.